Moberg Pharma AB (publ) (MOB) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, everyone, and thank you for joining the Moberg Pharma Q4 Report call. My name is Marie, and I will be coordinating your call today. During the presentation, you can register your question by pressing star followed by one on your telephone keypad. If you change your mind, please press star followed by two. I will now hand over to your host, Anna Leong, CEO, to begin. Please go ahead. Thank you, and good afternoon, everyone. Thank you for joining our Q4 earnings call today. I'm Anna Jöns, CEO of Moberg Pharma, and I also have our VP of Finance, Mark Beveridge, with me here today. We're happy to present our Q4 report that you can find on our webpage. There you can also find a PowerPoint presentation that I both based this call upon. This call will be recorded and uploaded to our webpage. In today's call, I will provide an overview of our performance this quarter, key business developments, and highlights to take into initiatives shaping our path forward. I am proud to report that Perklara continues to lead the Swedish market, achieving 31% market share in value and 25% in units for the full year in pharmacy sales and consumers, despite consumer marketing launching only in the beginning of April. Importantly, momentum continued in Q4, with figures reaching 33% in value and 26% in units, demonstrating demands for products continuing even in those seasons. These figures confirm the strengths of our product, marketing strategy, and our overall market leadership validates our execution and further underscores the potential for sustained expansion across Europe. Building upon this momentum, we are now expanding into Norway, a key milestone in our broadening European growth strategy. Initial deliveries have already been made, and we're launching pharmacy and healthcare ...